All Articles
Oncology Practice Management (OPM) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities. Read More ›
Oncology Practice Management (OPM) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities. Read More ›
The affordability of medication remains a substantial obstacle to care for many patients with cancer. According to the NCI, the per-patient annualized average costs of cancer diagnosis and treatment were highest in the last year of life, at $109,727 for medical services and $4372 for oral prescription drugs. Read More ›
Officials with the FDA approved durvalumab (Imfinzi; AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥4 cm and/or node positive) NSCLC and no known EGFR mutations or anaplastic lymphoma kinase rearrangements. Read More ›
On August 14, 2024, the FDA approved axatilimab-csfr (Niktimvo; Incyte Corporation), a colony-stimulating factor-1 receptor–blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least 2 prior lines of systemic therapy. Read More ›
Officials with the FDA approved lazertinib (Lazcluze; Janssen Biotech, Inc) in combination with amivantamab-vmjw (Rybrevant; Janssen Biotech, Inc) for the first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. Read More ›
On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (Tecelra; Adaptimmune, LLC), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or -cleared companion diagnostic devices. Read More ›
Lung cancer is the top cause of cancer death and the third most common cancer type in the United States, according to the National Cancer Institute. With an estimated 234,580 new cases of lung and bronchus cancer to be diagnosed in 2024 alone, this cancer will almost certainly affect a portion of your patients. Test your knowledge of this disease here. Read More ›
Breast cancer is the second most common cancer among women after skin cancer, according to the National Cancer Institute. In fact, in 2024 an estimated 310,720 cases will be diagnosed in women, representing 15.5% of all new cancers diagnosed that year, and 42,250 women with breast cancer will die. Test your knowledge of this widespread cancer. Read More ›